Antiviral therapy: why does it fail in HCV-related chronic hepatitis?

References

• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet349(9055), 825–832 (1997).
   PubMed Web of Science ®Google Scholar
• Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med.332(22), 1463–1466 (1995).
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchinson JG, Gordon SC et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet358, 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med.140, 346–355 (2004).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med.347, 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Heathcote EJ, Wedemeyer H et al. Sustained virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med.147, 677–684 (2007).
   PubMed Web of Science ®Google Scholar
• National Institute of Health Consensus Conference panel statement: management of Hepatitis C. Hepatology26(Suppl. 1), 2S–10S (1997).
   Google Scholar
• Manns M, Lindsay KL, Gordon SC et al. Sustained virological response after peginterferon alfa-2b and ribavirin treatment predicts long term clearance of HCV at 5-year follow-up. J. Hepatol.48, S300 (2008).
   PubMedGoogle Scholar
• Ohba K, Mizokami M, LauJYN et al. Evolutionary relationship of Hepatitis C, pesti-, flavi-, plantiviruses and newly discovered GB hepatitis agents. FEBS Lett.232–234 (1996).
   PubMedGoogle Scholar
• Bukh J, Miller RH, Purcell RH. Biology and genetic heterogeneity of Hepatitis C virus. Clin. Exp. Rheumatol.13(Suppl. 13), S3–S7 (1995).
   PubMed Web of Science ®Google Scholar
• Simmonds P, Bukh J, Combet C et al. Consensus proposal for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology42, 962–973 (2005).
   PubMed Web of Science ®Google Scholar
• Simmonds P. Genetic diversity and evolution of hepatitis C virus – 15 years on. J. Gen. Virol.85, 3173–3188 (2004).
   PubMed Web of Science ®Google Scholar
• Legrand-Abravanel F, Colson P, Leguillou-Guillemette H et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J. Med. Virol.81(12), 2029–2035 (2009).
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology49(4), 1335–1374 (2009).
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Eng. J. Med.325(25), 2609–2617 (2005).
   Google Scholar
• Dalgard O, Bjøro K, Hellum KB et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology40(6), 1260–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Von Wagner M, Huber M, Berg T et al. Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology129(2), 522–527 (2005).
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med.357(2), 124–134 (2007).
   PubMed Web of Science ®Google Scholar
• Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J. Infect. Dis.182, 698–707 (2000).
   PubMed Web of Science ®Google Scholar
• Hasan F, Asker H, Al-Khaldi J et al. Peg-Interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am. J. Gastroenterol.99, 1733–1737 (2004).
   PubMed Web of Science ®Google Scholar
• Kamal SM, El Tawil AA, Nakano T et al. Peginterferon (α)-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut54, 858–866 (2005).
   PubMed Web of Science ®Google Scholar
• Antaki N, Craxi A, Kamal S et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int.30(3), 342–355 (2010).
   PubMed Web of Science ®Google Scholar
• Antaki N, Hermes A, Hadad M et al. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J. Viral. Hepat.15, 383–386 (2008).
   PubMedGoogle Scholar
• Bonny C, Fontaine H, Poynard T et al. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment. Pharmacol. Ther.24, 593–600 (2006).
   PubMedGoogle Scholar
• Nguyen MH, Trinh HN, Garcia R et al. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am. J. Gastroenterol.103, 1131–1135 (2008).
   PubMedGoogle Scholar
• Li F, Ng TL, Tai LF et al. High response rate of combination therapy of pegylated interferon and ribavirin in treating chronic hepatitis C with genotype 6A in Hong Kong Chinese. Hepatol. Int.3, 164 (2009).
   Google Scholar
• Aurora R, Donlin MJ, Cannon NA et al. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J. Clin. Invest.119, 225–236 (2009).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology25, 740–744 (1997).
   PubMed Web of Science ®Google Scholar
• Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med.334, 77–81 (1996).
   PubMed Web of Science ®Google Scholar
• Donlin MJ, Cannon NA, Aurora R et al. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS ONE5(2), e9032 (2010).
   Web of Science ®Google Scholar
• Donlin MJ, Cannon NA, Yao E et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J. Virol.81(15), 8211–8224 (2007).
   PubMed Web of Science ®Google Scholar
• Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature436, 939–945 (2005).
   PubMed Web of Science ®Google Scholar
• Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks Peg-interferon α-2a (40 kd)/ribavirin therapy. Hepatology43, 954–960 (2006).
   PubMed Web of Science ®Google Scholar
• Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology37, 600–609 (2003).
   PubMed Web of Science ®Google Scholar
• Bárcena R, Moreno A, del Campo S et al. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1. Antivir. Ther.12(3), 401–406 (2007).
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M, Maylin S, Moucari R et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir. Ther.14, 501–511 (2009).
   PubMed Web of Science ®Google Scholar
• Maylin S, Martinot-Peignoux M, Ripault MP et al. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int.29, 511–517 (2009).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med.361, 580–593 (2009).
   PubMed Web of Science ®Google Scholar
• McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J. Viral Hepat.15(7), 475–481 (2008).
   PubMed Web of Science ®Google Scholar
• Mangia A, Minerva N, Bacca D et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology47(1), 43–50 (2008).
   PubMed Web of Science ®Google Scholar
• Escudero A, Rodriguez F, Serra MA et al. Pegylated α interferon-2a plus ribavirin compared with pegylated α-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J. Gastroenterol. Hepatol.23(6), 861–866 (2008).
   PubMedGoogle Scholar
• Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-[α]-2a and peginterferon-[α]-2b. Drugs70(2), 147–165 (2010).
   PubMed Web of Science ®Google Scholar
• Rumi MG, Aghemo A, Prati GM et al. Randomized study of peginterferon-α2a plus ribavirin vs peginterferon-α2b plus ribavirin in chronic hepatitis C. Gastroenterology138(1), 108–115 (2010).
   PubMed Web of Science ®Google Scholar
• Ascione A, De Luca M, Tartaglione MT et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology138(1), 116–122 (2010).
   PubMed Web of Science ®Google Scholar
• Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon α-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology51(4), 1176–1184 (2010).
   PubMed Web of Science ®Google Scholar
• Brok J, Gluud LL, Gluud C. Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitic C – an updated Cochrane review. Aliment. Pharmacol. Ther.32(7), 840–850 (2010).
   PubMedGoogle Scholar
• McHutchinson JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype 1 infected patients with chronic hepatitis C. Gastroenterology23, 1061–1069 (2010).
   Google Scholar
• Reddy KR, Shiffman ML, Morgan TR et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 completing peginterferon alfa-2a/ribavirin treatment. Clin. Gastroenterol. Hepatol.5, 124–129 (2007).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med.360, 1827–1838 (2009).
   PubMed Web of Science ®Google Scholar
• Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med.360, 1839–1850 (2009).
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet376(9742), 705–716 (2010).
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Nelson DR, Marcellin P. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care? Antivir. Ther.13(6), 747–760 (2008).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med.362, 1292–1303 (2010).
   PubMed Web of Science ®Google Scholar
• Floreani A, Minola E, Carderi I et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J. Am. Geriatr. Soc.54, 549–550 (2006).
   PubMedGoogle Scholar
• Antonucci G, Longo MA, Angeletti C et al. The effect of age on response to therapy with peginterferon α plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 year. Am. J. Gastroenterol.102, 1383–1391 (2007).
   PubMed Web of Science ®Google Scholar
• Huang CF, Yang JF, Dai CY et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J. Infect. Dis.201, 705–709 (2010).
   Google Scholar
• Nudo CG, Wong P, Hilzenrat N, Deschênes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can. J. Gastroenterol.20, 589–592 (2006).
   PubMed Web of Science ®Google Scholar
• Giannini EG, Basso M, Savarino V, Picciotto A. Predictive factors for response to peginterferon-α and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. Dig. Dis. Sci.55(11), 3193–3199 (2010).
   PubMedGoogle Scholar
• Di Marco V, Almasio PL, Ferraro D et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J. Hepatol.47, 484–491 (2007).
   PubMed Web of Science ®Google Scholar
• Melero J, Berenguer M. Antiviral therapy in patients with HCV-cirrhosis. Ann. Hepatol.8(4), 292–297 (2009).
   PubMedGoogle Scholar
• Heathcote EJ, Shiffman ML et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med.343, 1673–1680 (2000).
   PubMed Web of Science ®Google Scholar
• Iacobellis A, Siciliano M, Perri F et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J. Hepatol.46, 206–212 (2007).
   PubMed Web of Science ®Google Scholar
• Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who respond less well? Ann. Intern. Med.140(5), 370–371 (2004).
   PubMed Web of Science ®Google Scholar
• Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N. Engl. J. Med.350, 2265–2271 (2004).
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature461, 399–401 (2009).
   PubMed Web of Science ®Google Scholar
• Abu Mouch S, Fireman Z, Jarchovsky J et al. Vitamin D supplement improves SVR in chronic hepatitis C (Genotype 1) naive patients treated with Peg-interferon and ribavirin. J. Viral. Hepat.52(S1), S26 Abstract 55 (2010).
   Google Scholar
• Persico M, Iolascon A. Steatosis as a co-factor in chronic liver diseases. World. J. Gastroenterol.16(10), 1171–1176 (2010).
   PubMedGoogle Scholar
• Ortiz V, Berenguer M, Rayon JM et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am. J. Gastroenterol.97, 2408–2414 (2002).
   PubMed Web of Science ®Google Scholar
• Loguercio C, Federico A, Masarone M et al. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. Am. J. Gastroenterol.103(12), 3159–3166 (2008).
   PubMedGoogle Scholar
• Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int.29, 15–18 (2009).
   PubMed Web of Science ®Google Scholar
• Sheikh MY, Choi J, Qadri I et al. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology47(6), 2127–2133 (2008).
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol.165(5), 1499–1508 (2004).
   PubMed Web of Science ®Google Scholar
• Huang Y, Feld JJ, Sapp RK et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology132(2), 733–744 (2007).
   PubMedGoogle Scholar
• Persico M, Capasso M, Persico E et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology46(4), 1009–1015 (2007).
   PubMed Web of Science ®Google Scholar
• Persico M, Capasso M, Russo R et al. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut57(4), 507–515 (2008).
   PubMedGoogle Scholar
• Romero-Gòmez M, Diago M, Andrade RJ et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon Alfa-2a plus ribavirin. Hepatology50(6), 1702–1708 (2009).
   PubMed Web of Science ®Google Scholar
• Lin E, Hwang Y, Wang SC et al. An artificial neural network approach to the drug efficacy of interferon treatments. Pharmacogenomics7, 1017–1024 (2006).
   PubMed Web of Science ®Google Scholar
• Huang Y, Yang H, Borg BB et al. A functional SNP of interferon-gamma gene is important for interferon-α induced and spontaneous recovery from hepatitis C virus infection. Proc. Natl Acad. Sci. USA104, 985–990 (2007).
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon α and ribavirin therapy. Nat. Genet.41, 1100–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon α and ribavirin therapy for chronic hepatitis C. Nat. Genet.41, 1105–1119 (2009).
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure – a genome-wide association study. Gastroenterology138, 1338–1345 (2010).
   PubMed Web of Science ®Google Scholar
• Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol.4, 63–68 (2003).
   PubMed Web of Science ®Google Scholar
• Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons α and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology131, 1887–1898 (2006).
   PubMed Web of Science ®Google Scholar
• Mangia A, Thompson AJ, Santoro R et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology139(3), 821–827 (2010).
   PubMed Web of Science ®Google Scholar
• Chen L, Borozan I, Feld J et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology128, 1437–1444 (2005).
   PubMed Web of Science ®Google Scholar
• Paradis V, Asselah T, Dargere D et al. Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology130, 2189–2197 (2006).
   PubMedGoogle Scholar
• Jopling CL, Yi M, Lancaster AM et al. Modulation of hepatitis C virus RNA abundance by a liver-specific micro-RNA. Science309, 1577–1581 (2005).
   PubMed Web of Science ®Google Scholar
• Pedersen IM, Cheng G, Wieland S et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature449, 919–922 (2007).
   PubMed Web of Science ®Google Scholar
• Lanford RE, Hildebrandt-Eriksen ES, Petri A et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science327, 198–201 (2010).
   PubMed Web of Science ®Google Scholar